Chronic graft versus host disease (GVHD) is the most common complication of allogenic bone marrow transplantation. Because of the protracted clinical course of chronic GVHD, transplant centers and hematology/oncology offices are inadequately equipped to manage these immuno-incompetent patients with a multi-system disorder. Practitioners need to be able to recognize and effectively manage chronic GVHD as a late effect of more than half of allogenic transplantations. The text is oriented for the clinician, with chapters covering staging, organ site and system-specific manifestations, treatment options, and supportive care. Drs Georgia B. Vogelsang and Steven Z. Pavletic have been pioneers in the recognition of the multi-organ complexity of this disease and have gathered the input of a variety of subspecialist physicians for this book. This book fills the gap in practical literature on chronic GVHD, providing a comprehensive, up-to-date, and clinically relevant resource for anyone who deals with cancer patients post-transplant.
• Comprehensive, up-to-date, and clinically relevant resource for anyone who deals with cancer patients post-transplant • Oriented for clinicians, covers staging, organ site and system specific manifestations, treatment options, and supportive care • Interdisciplinary, with contributions from all medical subspecialties
- Part I. General Principles: 1. History Alois Gratwohl; 2. Pathophysiology of acute GVHD Carrie Kitko and James L. M. Ferrara; 3. Pathophysiology of chronic GVHD Kirk Schultz; 4. Animal models of chronic GVHD Yu-Wayne Chu, Ronald Gress, and Warren D. Shlomchik; 5. Incidence and trends Sally Arai, Mukta Arora, and Douglas Rizzo; 6. Clinical manifestations and natural history Mary Evelyn D. Flowers and Georgia Vogelsang; 7. Risk factors and predictive models Görgün Akpek and Stephanie J. Lee; 8. Biomarkers in prediction and monitoring Ernst Holler and Anne Dickinson;
- Part II. Clinical Management: 9. Diagnosis and staging Madan Jagasia, Howard M. Shulman, Alexandra H. Filipovich, and Steven Pavletic; 10. Chronic GVHD pharmacology and commonly used drugs T. Hughes and Timothy McGuire; 11. Prevention of chronic GVHD Andrea Bacigalupo and Nelson J. Chao; 12. Front line treatment of chronic GVHD Paul J. Martin and Andrew L. Gilman; 13. Salvage treatment of chronic GVHD Hildegard T. Greinix and Joseph H. Antin; 14. Response measurement David Jacobsohn, Sandra A. Mitchell, and Steven Z. Pavletic; 15. General principles in ancillary and supportive care Paul A. Carpenter and Dan R. Couriel;
- Part III. Organ Site or System Specific Manifestations: 16. Skin Edward W. Cowen and Sharon R. Hynes; 17. Mouth Nathaniel S. Treister, Mark M. Schubert, and Jane M. Fall-Dickson; 18. Eyes Stella K. Kim, Janine A. Smith, and James P. Dunn Jr.; 19. Genitalia Maria L. Turner and Pamela Stratton; 20. Gastrointestinal (including nutritional support) Miwa Sakai and George B. McDonald; 21. Pulmonary Javier Bolaños-Meade and Jason W. Chien; 22. Hematologic Corey Cutler; 23. Neurologic Harry Openshaw; 24. Musculoskeletal Li Li, Leighton Chan, and Lynn H. Gerber; 25. Infections Juan Gea-Banacloche and Michael Boeckh; 26. Metabolic and endocrine effects Paul A. Carpenter and Jean E. Sanders; 27. Other manifestations Kristin Baird and Andrew L. Gilman; 28. Psycho-social issues Loretta Williams and Karen L. Syrjala; 29. Secondary and late effects Gérard Socié and H. J. Deeg; 30. Quality of life assessments Sandra A. Mitchell and Bryce B. Reeve;
- Part IV. Special Considerations in Chronic GVHD: 31. Clinical trials design Paul J. Martin, Donna Przepiorka, and Stephanie J. Lee; 32. Unique clinical situations Mohamad Mohty, Juliet N. Barker, and Claudio Anasetti; 33. Pediatric chronic GVHD Kristin Baird, Alan S. Wayne, and David A. Jacobsohn; 34. Coordination and continuity of interdisciplinary practice Viki Anders, Carina Moravec, and Sandra A. Mitchell; 35. Patient and family education, advocacy, and support groups Kathleen M. Castro, Susan Stuart, Myra J. Jacobs, and Paula Kim; 36. Future directions Stephanie J. Lee.